Sanofi SNY announced a strategic collaboration with Teva Pharmaceuticals TEVA to co-develop and co-commercialize TEVA’s novel anti-TL1A therapy, TEV’574, for the treatment of Ulcerative Colitis and ...
Scores on a broad panel of blood metabolomic markers may predict inflammatory bowel disease (IBD) up to 10 years before onset, indicated a new study that leveraged population data from three countries ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback